NPO Microgen, a part Nacimbio holding company of Rostec Corporation, has completed the clinical trials of the first Russian botulinum toxin-based drug for the treatment of spastic forms of cerebral palsy (CP) in patients aged 13 to 17 years old.
“Until now, all medicines available in Russia for the treatment of spasticity in cases of cerebral palsy were foreign products. The results of clinical trials suggest that the Russian drug for the treatment of this disease is at least in no way inferior to the world analogs. In the near future, we also plan to complete the studies for using the drug in children aged 6 to 12 years old to treat this form of disease,” said Kirill Gaidash, the General Director of NPO Microgen.
The medicine is based on Relatox, the first Russian botulinum toxin type A-hemagglutinin complex. The clinical trials aimed at expanding the indications for its use have confirmed the safety and efficacy of the drug for treating the muscle spasticity of upper and lower limbs in children with cerebral palsy.
In March 2017, NPO Microgen confirmed the registration of the drug and received the registration certificate along with the inclusion of Relatox in the state register of medicinal products for an indefinite period.